Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0B3RL
|
|||
| Former ID |
DIB014291
|
|||
| Drug Name |
R-IFN-1a
|
|||
| Indication | Hepatitis C virus infection [ICD-11: 1E51.1; ICD-10: B18.2] | Phase 2 | [1] | |
| Company |
Merck-Serono Laboratories
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interferon alpha/beta receptor 1 (IFNAR1) | Target Info | Modulator | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| PI3K-Akt signaling pathway | ||||
| Osteoclast differentiation | ||||
| Toll-like receptor signaling pathway | ||||
| Jak-STAT signaling pathway | ||||
| Natural killer cell mediated cytotoxicity | ||||
| Hepatitis C | ||||
| Hepatitis B | ||||
| Measles | ||||
| Influenza A | ||||
| Herpes simplex infection | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Leptin Signaling Pathway | ||||
| Panther Pathway | Inflammation mediated by chemokine and cytokine signaling pathway | |||
| Pathway Interaction Database | Downstream signaling in naï | |||
| Reactome | Interferon alpha/beta signaling | |||
| Regulation of IFNA signaling | ||||
| WikiPathways | Toll-like receptor signaling pathway | |||
| Interferon type I signaling pathways | ||||
| Interferon alpha/beta signaling | ||||
| Regulation of toll-like receptor signaling pathway | ||||
| Osteoclast Signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | A phase II study of recombinant interferon-beta (r-hIFN-beta 1a) in combination with 5-fluorouracil (5-FU) in the treatment of patients with advanced colorectal carcinoma. Br J Cancer. 1997;75(3):423-6. | |||
| REF 2 | Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b. J Neurol Sci.1999 Oct 15;168(2):131-6. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.